Surgical trends in glaucoma management: The current Indian scenario

Ichhpujani, Parul; Singla, Ekta; Kalra, Gagan; Bhartiya, Shibal; Kumar, Suresh

doi:10.1007/s10792-021-02160-x

Cited by 3 publications

(2 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another one develops new MIGS devices to provide an alternative pathway through which aqueous humor can effectively exit the anterior chamber, reducing IOP (40)(41)(42). MIGS is widely becoming the front-line glaucoma surgery with respect to various advantages (43)(44)(45)(46)(47)(48).…”

Section: Glaucomamentioning

confidence: 99%

Grand Challenges and Opportunities in Surgical Ophthalmology: Together for a Shared Future

et al. 2022

View full text Add to dashboard Cite

Section: Glaucomamentioning

confidence: 99%

Grand Challenges and Opportunities in Surgical Ophthalmology: Together for a Shared Future

et al. 2022

View full text Add to dashboard Cite

“…To minimize a failure of trabeculectomy, anti-fi brotic agents such as 5-fl uorouracil and mitomycin C (MMC) have been widely used to improve the outcomes of the procedure (8)(9)(10). Although, minimal invasive glaucoma surgery is a promising procedure in OAG patients, trabeculectomy with MMC still remains the best option in certain patient populations (11,12). The use of MMC increases the effi cacy of trabeculectomy due to its potent antiproliferative effect, which prevents fi brosis of the fi lter pad, while consequently reducing the risk of fi ltration failure (13).…”

Section: Introductionmentioning

confidence: 99%

Surgical outcomes of trabeculectomy augmented with sub-Tenon injected mitomycin C

MAJTANOVA,

KERI,

KRISKOVA

et al. 2023

BLL

View full text Add to dashboard Cite

BACKGROUND: Recently, trabeculectomy with mitomycin C (MMC) where MMC is applied by injection into the Tenon layer has attracted close attention. However, the data on effi cacy and safety of this technique is still limited and more clinical studies are needed. Therefore, the work is aimed at comprehensive evaluation of the effectiveness of trabeculectomy using MMC applied by intra-Tenon injection. METHODS: A set of 50 eyes in 50 patients underwent trabeculectomy using MMC at concentration of 0.4 mg/ml in a total volume of 0.05 ml. The primary end point was to control intraocular pressure (IOP) on postoperative days 1, 8, 30 and 90 and subsequently at 6 and 12 months after surgery. The secondary end point was to evaluate the changes in various corneal parameters prior to and 90 days after surgical procedure. RESULTS: The mean preoperative IOP was 32.34 ± 9.45 mmHg. After surgery, the mean IOP signifi cantly decreased to 17.52 ± 4.58 mmHg at the 90-day follow-up, and to 18.14 ± 3.74 and 19.30 ± 3.82 mmHg at 6 and 12 months after the procedure, respectively. The mean BCVA values remained unchanged compared to baseline (0.77 ± 0.23) to the 90-day follow-up (0.80 ± 0.23). The mean number of anti-glaucoma medications signifi cantly reduced from 3.50 ± 0.74 to 0.58 ± 1.03 postoperatively. Similarly, the mean corneal hysteresis and ACD of the eye as well as CECD were signifi cantly changed postoperatively. CONCLUSIONS: Trabeculectomy using MMC applied by injection is a safe and effective surgical method for the treatment of primary and secondary forms of open-angle glaucoma. It has a signifi cant hypotonising effect and allows a complete discontinuation of antiglaucoma drugs (Tab.

show abstract

Identifying and categorizing compounds that reduce corneal transforming growth factor beta induced protein levels: a scoping review

Sciriha

Sultana

Borg

2022

Expert Review of Clinical Pharmacology

View full text Add to dashboard Cite

Surgical trends in glaucoma management: The current Indian scenario

Cited by 3 publications

References 29 publications

Grand Challenges and Opportunities in Surgical Ophthalmology: Together for a Shared Future

Grand Challenges and Opportunities in Surgical Ophthalmology: Together for a Shared Future

Surgical outcomes of trabeculectomy augmented with sub-Tenon injected mitomycin C

Identifying and categorizing compounds that reduce corneal transforming growth factor beta induced protein levels: a scoping review

Contact Info

Product

Resources

About